PMV Pharmaceuticals (NASDAQ:PMVP) Releases Quarterly Earnings Results

PMV Pharmaceuticals (NASDAQ:PMVP) released its quarterly earnings results on Tuesday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.18), FiscalAI reports.

PMV Pharmaceuticals Price Performance

NASDAQ:PMVP traded up $0.02 during mid-day trading on Wednesday, reaching $1.24. The company’s stock had a trading volume of 54,661 shares, compared to its average volume of 522,100. The company’s fifty day simple moving average is $1.39 and its two-hundred day simple moving average is $1.30. PMV Pharmaceuticals has a twelve month low of $1.02 and a twelve month high of $1.91. The stock has a market cap of $66.24 million, a P/E ratio of -0.87 and a beta of 1.52.

Analyst Ratings Changes

PMVP has been the subject of a number of analyst reports. Weiss Ratings raised shares of PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a research report on Friday, September 4th. Finally, Wall Street Zen cut shares of PMV Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $4.33.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company focused on developing therapies that target cancer-causing mutations in the tumor suppressor protein p53. The company aims to discover and develop small-molecule medicines designed to restore the normal tumor-suppressing function of mutant p53 proteins. PMV’s lead product candidate is rezatapopt, also known as PC14586, an investigational oral therapy designed to selectively target the p53 Y220C mutation. This mutation occurs in a range of solid tumors, and rezatapopt is being evaluated for its potential to reactivate the altered p53 protein and inhibit cancer-cell growth.